for personal use only - asx · 2016 in review –highlights from an exceptional year // 4 1. grew...
TRANSCRIPT
// 2
This presentation does not constitute investment, legal, taxation or other advice and the
presentation does not take into account your investment objectives, financial situation or particular
needs. You are responsible for forming your own opinions and conclusions on such matters and
should make your own independent assessment of the information presented. No responsibility is
accepted by dorsaVi or any of its respective officers, employees, agents, advisers or associates for
any of the information or for any action taken by you on the basis of that information. Any and all
use of the information is at your own risk.
Certain information may relate to protected intellectual property rights owned by dorsaVi Ltd (the
"Company”). Except as required by law, no representation or warranty, express or implied, is
made as to the accuracy, completeness or correctness of the information, opinions and
conclusions, or as to the reasonableness of any assumption contained in this presentation. By
receiving this information and to the extent permitted by law, you release dorsaVi and its
respective officers, employees, agents, advisers and associates from any liability (including,
without limitation, indirect or consequential loss or damage, or loss or damage arising by
negligence) arising as a result of the reliance by you or any other person on anything contained in
or omitted from this document or presentation.
DISCLAIMERF
or p
erso
nal u
se o
nly
// 3
INVESTMENT HIGHLIGHTS
• Global business targeting over $250bn market opportunity in OHS – FDA, CE Mark, TGA approved
• FY 16 revenue 2.3 times FY15:
• Strong start to Q217, following record Q117
• US 1H17 revenue on track to exceed US FY16 revenue
• US reimbursement supporting US roll out
• Large operational leverage:
• Costs stable – R&D and regulatory approval expense has been sunk
• US agency model resulting in rapid uptake
• Launch of smaller and easier to use v6 unit in February 2017:
• Expected to drive further sales growth and penetration
• Lower COGS, attractive margins and payback
• Annuity revenues emerging from the OHS ViSafe product:
• Successful launch in UK and US markets
• Signed first major customer Crown Resorts for myViSafe, strong pipeline of further large customersFor
per
sona
l use
onl
y
// 4
2016 IN REVIEW – HIGHLIGHTS FROM AN EXCEPTIONAL YEAR
1. Grew revenue from $1.35M to $3.0M, reduced expenditure by $1.4M
2. V6 sensor development on time and budget (App based, less COGS, cross platform and fast)
3. Successful launch of OHS ViSafe product into the UK and US markets with plan for annuity revenue
4. Achieved strong growth in clinical & sports markets with 350 devices in the field
5. Signed on with scale partners for US and UK clinical markets (Select Medical (US) & YPP (UK))
6. Launched agent model in the US to enable rapid uptake and revenue growth in OHS market
7. Existing reimbursement codes supporting US roll out
8. Reimbursement strategy progressed with the launch of registry sites lead by US Clinical KOLs
9. Launched a 3 year incentive program to reward exceptional performance of senior staff
10. Commercial pilots with medical device and pharma companies
For
per
sona
l use
onl
y
// 5
REVENUE UP 2.3 TIMES ON LOWER COST BASE
dorsaVi Ltd (ASX : DVL)
Share price $0.50
Shares on issue 149,914,616
Market capitalisation $75.0M
2013 2014 2015 2016 Q1 2017
Revenue 398,607 529,380 1,358,218 3,019,000 1,004,000*
EBITDA (2,148,749) (3,852,593) (8,684,709) (5,915,567) N/A
Loss from
continuing
operations
(1,659,235) (3,562,024) (8,036,161) (5,237,102) N/A
Cash position $13.97M $5.74M $6.04M $5.77M
142221 236
608
1,004
85
139
380
684
143
127
250
720
29
42
492
1,008
0
500
1,000
1,500
2,000
2,500
3,000
FY13 FY14 FY15 FY16 FY17
$ T
ho
usa
nd
dorsaVi Customer Revenue
Q4
Q3
Q2
Q1
*unaudited results
For
per
sona
l use
onl
y
// 6
STRONG GLOBAL GROWTH
UKAU US
$0.0M
$0.2M
$0.4M
$0.6M
$0.8M
$1.0M
$1.2M
$1.4M
$1.6M
$1.8M
$2.0M
FY2015 FY2016 FY2017 FY2015 FY2016 FY2017 FY2015 FY2016 FY2017
dorsaVi Sales Revenue
Q4
Q3
Q2
Q1
For
per
sona
l use
onl
y
// 8
Launch of myViSafe™
• Mini sensors
• Manual Handling App
• Video training
• Pre employment screening
MARKET EXCITED BY THE EASE OF APPLICATION
Dec 2016 Feb 2017 Apr 2017
New cloud-based
clinical application for:• Running
• Knee
New cloud-based
clinical application for:• Low Back
• Walking
• Functional
• Hamstring
For
per
sona
l use
onl
y
// 9
SUCCESSFUL LAUNCH OF OHS PRODUCT INTO US & UK
• Work injuries estimated to cost over $250B p.a. (US)
• Large untapped market with appetite for data
• Unique IP leading to reduced injuries & costs
• Interventions involving:
• Job assessment
• Equipment change
• Pre-employment screening
• Better decisions based on fact, not opinion
• Scalable business model driven through agents and insurers
• Market characterised by 1000s of corporates
For
per
sona
l use
onl
y
// 11
COMPELLING OFFERING LEADING TO ANNUITY REVENUE
Problem for major corporates:
• Lack of visibility on injuries and
costs
• Poor ability to understand and
change issues
dorsaVi offering:
• ViSafe projects (real data from
the field)
• Provides insights, risk matrix and
solutions
• Now offers an ongoing barometer
to identify risks through
myViSafe™
For
per
sona
l use
onl
y
// 12
ACHIEVED STRONG GROWTH IN CLINICAL & SPORTS
160 devices in
the market
24,000 physios
(0.5% penetration)
85 devices in
the market
48,000 physios
10 devices in FY15 80 devices in FY16
25 devices added in Q1 FY17
105 devices in the market
284,000 physical therapists
For
per
sona
l use
onl
y
// 13
CLINICAL PLATFORM TO MANAGE DATA, REPORTS AND
COMMUNICATION
Patient
Live Assessment Live Training Monitoring Biofeedback Exercises Reports
Doctor
Physio
Specialist
Employer
$
Insurer
Hospital
PATIENT REPORTS AND
DATA
For
per
sona
l use
onl
y
// 14
SIGNED WITH SCALE PARTNERS IN THE US & UK
Targeting large and company-owned franchise networks
• UK – YPP
• US – Relationship with Select Medical
Collaborative product development
• Product commercially released: ViPerform AMI
For
per
sona
l use
onl
y
// 15
LAUNCHED AGENT MODEL FOR RAPID REVENUE GROWTH
Scalable model:
• Direct sales representatives in
key markets
• Sales partnerships with agents
(win work & provide assessors)
• Insurers and Insurance Brokers
• Centralised analysis
Stages of OHS ViSafe work
For
per
sona
l use
onl
y
// 16
EXISTING REIMBURSEMENT CODES SUPPORTING US ROLL OUT
• Initial target of $35 per session through existing reimbursement code 97750
• Billing multiple codes per session (Average billing >$150 per session)
• Relationships building with groups like Select Medical and other groups
• Commercial pilot with Select Medical ahead of schedule (Aim: 20 devices in 12 months)
(Devices implemented in 24 of their 2,000 sites in 6 months)
• Pilot with Select Medical exceeding revenue targets (on revenue per device)
For
per
sona
l use
onl
y
// 17
REIMBURSEMENT STRATEGY PROGRESSED WITH REGISTRY
• US-based patient registry launched for low back pain to support reimbursement strategy
• Low Back Registry will recruit over 1,500 US-based low back pain patients in the first 18 months
• Initial 3 sites, headed by Washington DC-based PM&R Physician, Dr Mehul Desai
• Longitudinal study will monitor patient outcomes using ViMove
• Registry data will generate a series of medical publications highlighting the importance of ViMove data
• The registry forms part of dorsaVi’s reimbursement strategy for the US clinical market
For
per
sona
l use
onl
y
// 18
COMMERCIAL PILOTS WITH WORLD LEADERS
• Unique insights coming from these commercial research projects
• Each project will lead to multiple new publications and potential new IP
• 45,000 individual data sets and building daily
• Medical device and pharmaceutical companies now using dorsaVi as an outcome measure
65+RESEARCH PROJECTS
For
per
sona
l use
onl
y
// 20
CAPITAL RAISING
• dorsaVi Ltd (dorsaVi) intends to raise A$6.0-8.0m via a Placement and Share Purchase Plan (SPP) at $0.46
per share
• $3.0-5.0m Placement to sophisticated and institutional investors under listing rule 7.1 and 7.1A
• $2.0m to be subscribed for by major shareholder Starfish, subject to shareholder approval at the EGM to
be held in January 2017. Starfish will be scaled back by up to $1.0m if institutional placement is
oversubscribed.
• $1.0m Share Purchase Plan to existing shareholders
• Funds will be used for:
• Recruitment and signing of additional OHS agents in the US to rapidly scale revenue
• Working capital to fund new product launch of v6 in anticipation of sales growth
• General working capital
• Summary of outlook for 2017:
• Revenue growth to continue into 2017 – Q2 performing to expectations
• US revenue growing strongly – 1H17 expected to exceed FY16
• Further US agents to be signed in new states - supporting ongoing US sales growth
• Costs to remain stable from FY16 – large operational leverage
• Launch of v6 to clinical market in February 2017 expected to drive further sales, lower COGS and
improved margins
• Expecting to sign additional large myViSafe customers like Crown Resorts – will grow annuity
revenue base
For
per
sona
l use
onl
y
// 21
CAPITAL RAISING
Indicative Timetable*
Company in trading halt Friday 9th December 2016
SPP record date Monday 12th December 2016
Capital raising announced and resumption of ASX trading Tuesday 13th December 2016
Dispatch SPP offer documents to eligible shareholders Wednesday 14th December 2016
SPP opens Wednesday 14th December 2016
Placement settlement (Tranche 1) Friday 16th December 2016
Placement allotment (Tranche 1) Monday 19th December 2016
SPP closes Thursday 19th January 2017
EGM to approve Starfish placement Friday 20th January 2017
Starfish placement subscription and allotment Monday 23rd January 2017
*The company reserves the right to vary these dates
For
per
sona
l use
onl
y
// 24BOARD AND SENIOR MANAGEMENT
Non Executive Director
Michael Panaccio
Chairman
Herb Elliott
Non Executive Director
Greg Tweedly
Non Executive Director
Ash Attia
Director & CEO
Andrew Ronchi
CFO
Damian Connellan
CIO
Meagan Blackburn
CPO
Muhammad Umer
CMO
Megan Connell Head of Sales and
Operations Europe
Zoë Whyatt
Head of Sales and
Operations Australia
Matt May
Head of Sales and
Operations US
Mark Heaysman
For
per
sona
l use
onl
y
// 25
OUR BUSINESS: SOLID FOUNDATION FOR GROWTH
• Three key business divisions with diversified revenue streams
• Organisational health and safety
• Clinical
• Elite sports
• Market leader with first mover advantage
• Patent protected technology
• Significant barriers to entry and limited competition
• FDA approval
• TGA approval
• CE Mark
• Currently focused on three key geographies
• United States
• United Kingdom
• AustraliaFor
per
sona
l use
onl
y
// 26
THE HARDWARE AND PRODUCTS
• Patent protected movement algorithms
on medical-grade sensor technology
• Function-specific applications which
deliver meaningful movement data to our
target markets
• OHS solution to determine, measure and mitigate high risk activities
• Significant appetite for innovative manual handling solutions
• Executive and board-level focus on reducing injuries and
associated costs
• Budget readily available
• Clinical solution with turnkey applications for low back, running and a
range of other functional measures
• Early adopter advocates in key geographic markets of
Australia, USA and UK
• Distribution partners in USA and UK
• Elite sporting solution used in off-field environments
to measure stress and prevent injury
• Widespread use across many codes – AFL,
NRL, NBA, NFL
• Sporting business growing via word of
mouth
For
per
sona
l use
onl
y
// 28
dorsaVi™
Andrew Ronchi
PhD (Eng), B.App.Sci (Physio)
Chief Executive Officer
Level 1, 120 Jolimont Road,
East Melbourne, Victoria 3002
Office: +61 9652 2192 | Mobile: +61 417 882 267
[email protected] | dorsaVi.com
For
per
sona
l use
onl
y